Clinical trial NCT05343143: NeuraGen 3D Pilot Study
Official title: An Open-Label, Multicenter, Pilot Study to Evaluate the Performance and Safety of NeuraGen® 3D Nerve Guide Matrix.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Digital Nerve Injury
Lead sponsor: Integra LifeSciences Corporation
Sponsor class: INDUSTRY
First posted: 2022-04-25
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: single arm investigational clinical trial
Primary purpose: TREATMENT

Brief summary: This is a 10-subject, 12-month follow-up, prospective, multi-center, open-label, single arm clinical trial designed to understand the initial performance characteristics and confirm the safety profile of the NeuraGen 3D Nerve Guide Matrix.

Detailed description: The NeuraGen® 3D Nerve Guide Matrix is indicated for the repair of peripheral nerve discontinuities where tension-free closure can be achieved by flexion of the digit or extremity.

Eligibility criteria: Key Inclusion Criteria:

* Subject has one, single level, digital nerve injury that:
* Involves complete traumatic nerve section of the common or proper nerve of the palmar aspect of hand.
* Occurred less than and up to 21 days prior to the nerve repair surgery detailed in this protocol.
* In the opinion of the investigator, has a gap which can be easily closed without placing undue tension on the ends of the nerves with the device (i.e., the gap must be shorter than the maximum length of the device being used).
* Subject has adequate vascular perfusion of the target hand as assessed by the investigator
* Subject can accommodate immobilization of the injured hand post-operatively.
* Subject's contralateral hand is intact and of normal function.

Exclusion Criteria:

* Nerve to be repaired is a mixed motor nerve
* Subject has a known history of hypersensitivity to bovine-derived or chondroitin-based materials.
* Subject's hand injury is of a nature which could negatively impact healing of the target nerves such as a crush or avulsion injury, incomplete transection of the target nerve, or complete separation of the digit affiliated with the target nerve.
* Subject's hand injury or general physical presentation of the target hand is of a nature which would prevent adequate measurement of functional nerve healing assessments.
* Subject has gross contamination of the wound in which the nerve to be studied in this protocol resides (i.e., presence of glass, metal, other large debris).
* Subject has pre-existing nerve lesions or known diagnosis of compressive neuropathy of median or ulnar nerves (i.e., Cubital or carpal tunnel syndrome).
* Subject has an active infection of the area around the nerve defect.
* Subject has unstable vital signs.
* Subject has a disorder known to affect the peripheral nervous system (PNS) such as:
* Subject has any systemic disease which may confound study results Subject is known to have received immunosuppressive or antineoplastic agents or systemic steroids within 7 days of the study.
* Subject is known to have had or will require radiation or other therapy to the target hand or limb which may impact nerve healing.
* Subject has a history of injury to or a congenital abnormality of the target hand or limb which may impact nerve healing or confound study results.
* Subject is pregnant (determined either by the subject's confirmation or a formal test).
* Subject has participated in another clinical trial using an investigational drug or device within 30 days prior to the nerve repair surgery detailed in this protocol.

Primary outcomes:
measure: The primary objective of this study is to evaluate return to sensory recovery with the NeuraGen 3D Nerve Guide Matrix in a small group of subjects with primary nerve injury of the hand.(s2PD) at each post-operative timepoint of the study.
timeFrame: 12 Months
Secondary outcomes:
measure: Moving 2 Point Discrimination Test (m2PD) at each post-operative timepoint of the study:
timeFrame: 12 Months
measure: Grip Strength Test at each post-operative timepoint of the study
timeFrame: 12 Months
measure: Pinch Strength Test at each post-operative timepoint of the study
timeFrame: 12 Months
measure: Semmes-Weinstein Monofilament Testing at each post-operative timepoint of the study
timeFrame: 12 Months
measure: Disabilities of the Arm, Shoulder and Hand (DASH) Score at each post-operative timepoint of the study
timeFrame: 12 Months
measure: Michigan Hand Outcomes Questionnaire (MHQ) at each post-operative timepoint of the study
timeFrame: 12 Months
measure: Continuous Visual Analog Scale for Pain at each post-operative timepoint of the study
timeFrame: 12 Months
Other outcomes:
Locations:
city: New York
country: United States
facility: Hospital for Special Surgery
state: New York
city: Durham
country: United States
facility: Duke University
state: North Carolina
city: Columbus
country: United States
facility: The Ohio State University Wexner Medical Center
state: Ohio
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center
state: Pennsylvania
Study officials:
affiliation: Integra LifeSciences
name: Maria Leonard
role: STUDY_DIRECTOR
References: